Novo Nordisk gets Form 483 from FDA after inspection at Plainsboro, NJ site

Wednesday, March 11, 2026 (Greg Slabodkin)View original

The Danish drugmaker received a warning letter from the agency related to a Post-marketing Adverse Drug Experience inspection conducted last month.

Read the full article on the original site.